Back to News
Market Impact: 0.25
Lakewood-Amedex Secures IRB Approval To Begin Nu-3 Phase 2a Study In Infected Diabetic Foot Ulcer
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Lakewood-Amedex Biotherapeutics obtained central and site-level Institutional Review Board approvals and confirmed trial-site readiness to begin its Phase 2a clinical trial. The regulatory and operational milestones advance the clinical-stage biotech's development program, though no efficacy, safety, financial, or enrollment details were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
LABT0.60
More News
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- ‘The nail that sticks out gets hammered first’: Elon Musk’s net worth falls $113 billion from Tesla and SpaceX drops
- Stock Selloff Eases After $3 Trillion Rout
- EU charges TikTok over harmful algorithmic 'rabbit hole' effects
- Tesla is 'winding down' Cybertruck production at its Texas Gigafactory